Cyclo Therapeutics Stock Price, News & Analysis (NASDAQ:CYTH) $1.32 +0.01 (+0.76%) (As of 05:28 PM ET) Add Compare Share Share Today's Range$1.29▼$1.4950-Day Range$0.93▼$1.6952-Week Range$0.67▼$2.57Volume38,195 shsAverage Volume92,995 shsMarket Capitalization$30.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cyclo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.5% Upside$4.00 Price TargetShort InterestBearish2.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector756th out of 958 stocksBiological Products, Except Diagnostic Industry113th out of 143 stocks 3.5 Analyst's Opinion Consensus RatingCyclo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Cyclo Therapeutics has a forecasted upside of 198.5% from its current price of $1.34.Amount of Analyst CoverageCyclo Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.57% of the float of Cyclo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclo Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Cyclo Therapeutics has recently increased by 76.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCyclo Therapeutics does not currently pay a dividend.Dividend GrowthCyclo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYTH. Previous Next 2.7 News and Social Media Coverage News SentimentCyclo Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for CYTH on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows3 people have added Cyclo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.03% of the stock of Cyclo Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclo Therapeutics has a P/B Ratio of 19.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cyclo Therapeutics Stock (NASDAQ:CYTH)Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.Read More CYTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTH Stock News HeadlinesNovember 29, 2023 | businesswire.comAPPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied ...November 21, 2023 | finance.yahoo.comCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024December 7, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 15, 2023 | msn.comCyclo Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 10, 2023 | seekingalpha.comWISH, REAL and PIXY among mid-day moversNovember 2, 2023 | finance.yahoo.comSeveral Insiders Invested In Cyclo Therapeutics Flagging Positive NewsOctober 30, 2023 | finance.yahoo.comRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsDecember 7, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 23, 2023 | finance.yahoo.comCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionOctober 5, 2023 | finance.yahoo.comCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceSeptember 21, 2023 | tmcnet.comCYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to ShareholdersSeptember 21, 2023 | finance.yahoo.comCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementAugust 15, 2023 | finance.yahoo.comCyclo Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | benzinga.comCyclo Therapeutics And This Other Penny Stock Insiders Are BuyingJune 12, 2023 | benzinga.comCyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's DiseaseMay 22, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Cyclo Therapeutics StockMay 15, 2023 | finance.yahoo.comCyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comCyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)April 28, 2023 | benzinga.comCyclo Therapeutics Stock (NASDAQ:CYTH), Guidance and ForecastApril 21, 2023 | finance.yahoo.comCyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 21, 2023 | msn.comCyclo Therapeutics's Return On Capital Employed InsightsMarch 20, 2023 | marketwatch.comCyclo Therapeutics in Talks About Possible CombinationMarch 20, 2023 | finance.yahoo.comCyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial ResultsMarch 15, 2023 | seekingalpha.comCYTH Cyclo Therapeutics, Inc.March 10, 2023 | benzinga.comCyclo Therapeutics Chief Operating Officer Awarded $44K Worth of Stock OptionsMarch 10, 2023 | benzinga.comCyclo Therapeutics Chief Regulatory Officer Awarded $44K Worth of Stock OptionsSee More Headlines Receive CYTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/17/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTH CUSIPN/A CIK922247 Webwww.ctd-holdings.com Phone(386) 418-8060Fax321-244-8351Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+198.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,450,000.00 Net Margins-2,037.29% Pretax Margin-2,037.19% Return on Equity-1,706.53% Return on Assets-418.15% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.80 Sales & Book Value Annual Sales$951,809.00 Price / Sales32.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book19.14Miscellaneous Outstanding Shares22,732,000Free Float15,962,000Market Cap$30.46 million OptionableNot Optionable Beta-0.04 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. N. Scott Fine (Age 66)CEO & Director Comp: $877.88kMr. C. E Strattan (Age 77)Founder & Director Comp: $44kMr. Joshua M. Fine (Age 41)CFO & Secretary Comp: $509.38kMr. Michael Eric Lisjak (Age 50)Chief Regulatory Officer & Senior VP of Business Development Comp: $505.9kDr. Jeffrey L. Tate Ph.D. (Age 65)COO, Chief Quality Officer & Director Comp: $255.14kMs. Lori McKenna GorskiGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical OfficerMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXIN8bioNASDAQ:INABGamida CellNASDAQ:GMDAPassage BioNASDAQ:PASGAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInsidersRafael Holdings, Inc.Bought 4,000,000 shares on 8/1/2023Total: $5 M ($1.25/share)N Scott FineBought 299,402 shares on 4/20/2023Total: $212,575.42 ($0.71/share)Markus SiegerBought 59,881 shares on 4/20/2023Total: $42,515.51 ($0.71/share)Jeffrey TateBought 29,941 shares on 4/20/2023Total: $21,258.11 ($0.71/share)View All Insider Transactions CYTH Stock Analysis - Frequently Asked Questions Should I buy or sell Cyclo Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTH shares. View CYTH analyst ratings or view top-rated stocks. What is Cyclo Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 1-year target prices for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 198.5% from the stock's current price. View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts. How have CYTH shares performed in 2023? Cyclo Therapeutics' stock was trading at $1.42 on January 1st, 2023. Since then, CYTH shares have decreased by 5.6% and is now trading at $1.34. View the best growth stocks for 2023 here. Are investors shorting Cyclo Therapeutics? Cyclo Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 223,000 shares, an increase of 76.4% from the October 31st total of 126,400 shares. Based on an average daily volume of 55,400 shares, the short-interest ratio is currently 4.0 days. Approximately 2.6% of the company's stock are short sold. View Cyclo Therapeutics' Short Interest. When is Cyclo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our CYTH earnings forecast. How were Cyclo Therapeutics' earnings last quarter? Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.34. The business earned $0.19 million during the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 1,706.53% and a negative net margin of 2,037.29%. How do I buy shares of Cyclo Therapeutics? Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CYTH) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.